While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top AI stocks ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, Inc. announced Thursday an agreement designed to ...

In Jewish communities, conversations about genetic risks often focus on BRCA mutations and breast ... Dr. McNally sent my sister’s DNA for genetic testing, but it didn’t have mutations in ...

acting as a 'pre-screen' for BRCA mutations (BRCAm) that can then be confirmed with a regular genetic test. The germline BRCA (gBRCA) pre-screen programme has grown out of Owkin's ongoing ...

MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...